title: Effect of recombinant human erythropoietin on soluble interleukin 2 receptor (SIL-2R) levels in haemodialysis patients.
authors.forename: B
authors.initials: B
authors.lastname: Altun
authors.forename: Y
authors.initials: Y
authors.lastname: Erdem
authors.forename: I
authors.initials: I
authors.lastname: Haznedaroğlu
authors.forename: M
authors.initials: M
authors.lastname: Gürsoy
authors.forename: U
authors.initials: U
authors.lastname: Yasavul
authors.forename: C
authors.initials: C
authors.lastname: Turgan
authors.forename: S
authors.initials: S
authors.lastname: Cağlar
authors.forename: S
authors.initials: S
authors.lastname: Kirazli
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000097:blood / Q000188:drug therapy*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000187:drug effects / Q000378:metabolism*; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis
chemical_list: D015375:Receptors, Interleukin-2; D011994:Recombinant Proteins; D004921:Erythropoietin